Feed / GH

Guardant Health, Inc.

GH

Healthcare · 170.76 +1.8% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Guardant Health, Inc.'s move is being confirmed by its market group.

GH accounts for 8.8% of the group's measured movement across 7.3 effective names. raw member direction is mixed; 6 of 10 SPY-adjusted paths align to the upside. Capital-flow agreement is 53%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#5 of 10 by movement share
Group movement share8.8%Absolute path energy—not portfolio weight
Relative path+2.18%aligned
Effective breadth7.3 / 10broad
Relative alignment6/10upside path · 4 counter-moving
Capital-flow agreement53%not yet clean
SEQUENCE READ

GH was the first measured mover. GH crossed its material path threshold at 10:20 ET. COGT, NTRA, VCYT followed.

What changed
  • Revenue increased 48.3% versus the comparable filing period.
  • The operating loss widened by 10.3M.
EVIDENCE COVERAGE

5 of 10 members in Cancer Diagnostics are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 7 of 10 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as MYGN begins moving with the group.

Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.

Watch this read

Who this business touches

The relationships behind GH

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AMGNAmgen Inc.supplierFeb 19, 2026 ▾

“The MHLW additionally granted regulatory approval of the Guardant360 CDx liquid biopsy test as a companion diagnostic for identifying patients with metastatic NSCL cancer who may benefit from treatment with LUMAKRASTM (sotorasib), a KRAS G12C inhibitor develo…”

PANWPalo Alto Networks, Inc.partnerOct 29, 2025 ▾

“In addition, our Redwood City, San Diego and Palo Alto, California laboratories are currently operated as centers for our research and technology development, and our Palo Alto laboratory is also CLIA licensed.”

Depended on by

BLLNBillionToOne, Inc.competitorMar 11, 2026 ▾

“In the oncology market, our main competitors for our therapy selection and response monitoring tests include Caris Life Sciences, Inc., Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Guardant Health, Inc., NeoGenomics Laboratories, Inc…”

Filing peers

NTRAMYGNQUCY

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 20 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

GH is currently a Early Follower in the organic co-movement group Cancer Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.